RT Journal Article
T1 Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study.
A1 Torres, Antoni
A1 Motos, Ana
A1 Cilloniz, Catia
A1 Ceccato, Adrian
A1 Fernandez-Barat, Laia
A1 Gabarrus, Albert
A1 Bermejo-Martin, Jesus
A1 Ferrer, Ricard
A1 Riera, Jordi
A1 Perez-Arnal, Raquel
A1 Garcia-Gasulla, Dario
A1 Peñuelas, Oscar
A1 Lorente, Josa Angel
A1 de Gonzalo-Calvo, David
A1 Almansa, Raquel
A1 Menendez, Rosario
A1 Palomeque, Andrea
A1 Villar, Rosario Amaya
A1 Añon, Jose M
A1 Balan Mariño, Ana
A1 Barbera, Carme
A1 Barberan, Jose
A1 Blandino Ortiz, Aaron
A1 Boado, Maria Victoria
A1 Bustamante-Munguira, Elena
A1 Caballero, Jesus
A1 Canton-Bulnes, Maria Luisa
A1 Carbajales Perez, Cristina
A1 Carbonell, Nieves
A1 Catalan-Gonzalez, Mercedes
A1 de Frutos, Raul
A1 Franco, Nieves
A1 Galban, Cristóbal
A1 Gumucio-Sanguino, Víctor D
A1 de la Torre, Maria Del Carmen
A1 Diaz, Emili
A1 Estella, Angel
A1 Gallego, Elena
A1 Garcia Garmendia, Jose Luis
A1 Gomez, Jose M
A1 Huerta, Arturo
A1 Garcia, Ruth Noemi Jorge
A1 Loza-Vazquez, Ana
A1 Marin-Corral, Judith
A1 Martin Delgado, Maria Cruz
A1 Martinez de la Gandara, Amalia
A1 Martinez Varela, Ignacio
A1 Lopez Messa, Juan
A1 Albaiceta, Guillermo M
A1 Nieto, Maite
A1 Novo, Mariana Andrea
A1 Peñasco, Yhivian
A1 Perez-Garcia, Felipe
A1 Pozo-Laderas, Juan Carlos
A1 Ricart, Pilar
A1 Sagredo, Victor
A1 Sanchez-Miralles, Angel
A1 Sancho Chinesta, Susana
A1 Serra-Fortuny, Mireia
A1 Socias, Lorenzo
A1 Sole-Violan, Jordi
A1 Suarez-Sipmann, Fernando
A1 Tamayo Lomas, Luis
A1 Trenado, Jose
A1 Ubeda, Alejandro
A1 Valdivia, Luis Jorge
A1 Vidal, Pablo
A1 Barbe, Ferran
K1 COVID-19
K1 Corticosteroids
K1 Critically ill
K1 Intensive care
AB Although there is evidence supporting the benefits of corticosteroids in patients affected with severe coronavirus disease 2019 (COVID-19), there is little information related to their potential benefits or harm in some subgroups of patients admitted to the intensive care unit (ICU) with COVID-19. We aim to investigate to find candidate variables to guide personalized treatment with steroids in critically ill patients with COVID-19. Multicentre, observational cohort study including consecutive COVID-19 patients admitted to 55 Spanish ICUs. The primary outcome was 90-day mortality. Subsequent analyses in clinically relevant subgroups by age, ICU baseline illness severity, organ damage, laboratory findings and mechanical ventilation were performed. High doses of corticosteroids (≥ 12 mg/day equivalent dexamethasone dose), early administration of corticosteroid treatment ( Between February 2020 and October 2021, 4226 patients were included. Of these, 3592 (85%) patients had received systemic corticosteroids during hospitalisation. In the propensity-adjusted multivariable analysis, the use of corticosteroids was protective for 90-day mortality in the overall population (HR 0.77 [0.65-0.92], p = 0.003) and in-hospital mortality (SHR 0.70 [0.58-0.84], p  Corticosteroid in ICU-admitted patients with COVID-19 may be administered based on age, severity, baseline inflammation, and invasive mechanical ventilation. Early administration since symptom onset may prove harmful.
PB Springer
YR 2022
FD 2022-05-01
LK http://hdl.handle.net/10668/19575
UL http://hdl.handle.net/10668/19575
LA en
NO Torres A, Motos A, Cillóniz C, Ceccato A, Fernández-Barat L, Gabarrús A, et al. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med. 2022 Jul;48(7):850-864.
DS RISalud
RD Apr 11, 2025